Publications of Matthias Fischer
All genres
Journal Article (13)
2019
Journal Article
79 (21), pp. 5652 - 5667 (2019)
Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface. Cancer Research: an official organ of the American Association for Cancer Research 2017
Journal Article
23 (10), pp. 2433 - 2441 (2017)
A phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clinical Cancer Research
Journal Article
6 (3), e1320626 (2017)
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology
Journal Article
8 (49), pp. 85234 - 85251 (2017)
Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma. Oncotarget 2016
Journal Article
7 (11), pp. 1383 - 1387 (2016)
Anti-ALK antibodies in patients with ALK-positive malignancies not expressing NPM-ALK. Journal of Cancer
Journal Article
7 (41), pp. 66344 - 66359 (2016)
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget
Journal Article
14 (1), 142 (2016)
An 18 gene expression‑based score classifier predicts the clinical outcome in stage 4 neuroblastoma. Journal of Translational Medicine
Journal Article
15 (3), pp. 311 - 312 (2016)
Telomere maintenance is pivotal for high-risk neuroblastoma. Cell Cycle
Journal Article
10 (2), pp. 344 - 359 (2016)
Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Molecular Oncology
Journal Article
16 (4), pp. 979 - 993 (2016)
Regulation of nuclear hormone receptors by MYCN-driven miRNAs impacts neural differentiation and survival in neuroblastoma patients. Cell Reports
Journal Article
65, pp. 91 - 101 (2016)
Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. European Journal of Cancer 2015
Journal Article
7 (312), 312ra176 (2015)
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Science Translational Medicine
Journal Article
8 (408), ra130 (2015)
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Science Signaling